Elasmogen, a biotech spin-out of Aberdeen University, secures US patent for its immunisation technology derived from sharks.
Elasmogen, a life sciences firm developing variable new antigen receptor (VNAR) protein drugs derived from sharks, has bolstered its global intellectual property standing by acquiring a US patent.
VNAR technology developed at Aberdeen University, which Elasmogen is commercialising, is already patented in several other parts of the world, and has been used to generate compounds against inflammatory disease and cancer.
VNARs in sharks play a similar role to antibodies in humans, but are the smallest in the natural world, at…
